IL18 and cancer: Previous studies have indicated that the activation of NLRP3 inflammasome can contribute to cancer progression by releasing inflammatory cytokines such as IL-1β and IL-18 (Vidal-Vanaclocha et al., 2000; Fabbi et al., 2015; Fenini et al., 2017).